• The Debate over Ending Social Distancing to Save the Economy, Explained

    “America will again, and soon, be open for business,” President Donald Trump said on Monday. “Very soon. A lot sooner than three or four months that somebody was suggesting. A lot sooner. We cannot let the cure be worse than the problem itself.”
    Ezra Klein writes in Vox that the cure, in this case, is social distancing, and the mass economic stoppage it forces. The problem is Covid-19, and the millions of deaths it could cause. On Tuesday, Trump accelerated his timeline. He said he’d like to see normalcy return by Easter Sunday, which is 12 April. “Wouldn’t it be great to have all the churches full?” he asked. “You’ll have packed churches all over our country.”
    Public health experts reacted with horror. “But the question Trump is posing needs to be taken seriously,” Klein writes. “The costs of social distancing are tremendous. The economic forecasts now predict a GDP drop and an unemployment rate of Great Depression-level proportions. The human suffering that will be unleashed is real, and it is vicious.”

  • Online Economic Decision Tool to Help Communities Plan for Disaster

    Preparing a community’s buildings and infrastructure for a hurricane or earthquake can be an incredibly complicated and costly endeavor. A new online tool from NIST could streamline this process and help decision makers invest in cost-effective measures to improve their community’s ability to mitigate, adapt to and recover from hazardous events.

  • COVID-19 Preventative Vaccine Trial for Healthcare Workers

    Professor Kathryn North AC, Director of the Murdoch Children’s Research Institute in Melbourne, Australia, has announced its infectious disease researchers are preparing to roll-out a multi-center randomised controlled clinical trial of the BCG vaccine against COVID-19. 
    The trial has been endorsed by the Director-General of the WHO, Tedros Adhanom, who has called for global support and assistance in the fight against COVID-19.  

  • Chloroquine and Hydroxychloroquine: No Proof These Anti-Malarial Drugs Prevent Novel Coronavirus in Humans

    There’s worrying news around the world of people self-medicating at home with the drugs chloroquine and hydroxychloroquine to treat COVID-19. Chloroquine is not yet proven to work against COVID-19, though news reports originating in China have speculated otherwise. But theories about chloroquine and COVID-19 have spread around the world, despite a lack of hard evidence about the value of chloroquine in preventing or treating COVID-19. No one should be self-treating with chloroquine or hydroxychloroquine for COVID-19 as there is currently no proof they can cure the infection – and accidental harm is more likely if they are used in this way.

  • Initial Results of a New Symptom Tracking App: About 10% of Britons Are Infected

    The first app monitoring symptoms of people in Britain with suspected coronavirus shows that, at present, one in 10 users have a mild form of the virus at present. The app, developed by researchers in King’s College London, was made available to the public on Wednesday. Within the first 24 hours of the app being made available, some 650,000 people had signed up – and an initial analysis revealed that 10 percent of people were showing mild symptoms of the virus.

  • App Helps Doctors Find the Right Dose of Corona Medication

    Researchers have developed an app that doctors can use to more easily determine the right dosage of medication for corona patients. At the moment, doctors are prescribing many existing kinds of medication to patients. Using the app, they can determine a safe and effective dosage.

  • How to Model a Pandemic

    There is, however, a little known but highly successful field of science working in the background to unpick the mysteries of infectious disease. As I explore in The Maths of Life and Death, mathematical epidemiology is playing a crucial role in the fight against large-scale infectious diseases such as COVID-19.

  • Reducing U.S. Fossil-Fuel Dependence: Left, Right Agree on Goal, Differ on Means

    Both sides of the political spectrum recognize a need to reduce American dependence on carbon-based energy sources, but how the nation does so remains a divisive issue, a new study found.

  • Body Armor for Women in Law Enforcement

    Law enforcement in the United States remains a male-dominated profession. According to recent reports, less than 13 percent of full-time officers are female. So, it stands to reason that the ballistic-resistant body armor worn by law enforcement officers in the field has traditionally been designed for the male build. As the number of women entering the field continues to rise, so too has the demand for personal protective equipment (PPE) that is designed for the female physique.

  • Protecting U.S. Energy Grid and Nuclear Weapons Systems

    To deter attempts to disable U.S. electrical utilities and to defend U.S. nuclear weapon systems from evolving technological threats, Sandia researchers have begun two multiyear initiatives to strengthen U.S. responses.

  • Which Covid-19 Drugs Work Best?

    Results are in from the first organized trials of drugs to treat Covid-19, but so far, there’s no cure.
    Antonio Regalado writes in MIT Technology Review that as the new respiratory disease spread widely starting in January, doctors—first in China and then in the US, Italy, and France—all moved to test readily available drugs that are used for other purposes and are fairly safe. Now, just three months into the pandemic, the first medical results from organized trials—studies structured to measure whether a drug actually helps—are becoming public. We count three so far, all involving drugs with antiviral properties. He offers a detailed report on the facts about the drug studies published so far.

  • HIV Drug to Be Trialed on Coronavirus Patients to See If It Can Fight COVID-19

    Coronavirus patients will be treated with an HIV drug or steroid as part of trial to see if existing medications can beat the deadly infection. Sarah Knapton reports in The Telegraph that researchers from the University of Oxford enrolled the first patient last week, and want hospitals to sign up thousands more people in the coming weeks. The trial – which has been expedited by the chief medical officer, Professor Chris Whitty – would usually have taken around 18 months to organize, but red tape has been removed and researchers have worked round the clock to get the experiment up and running within just nine days.

  • There's a New Symptom of Coronavirus, Doctors Say: Sudden Loss of Smell or Taste

    A loss of a sense of smell or taste may be a symptom of COVID-19, medical groups representing ear, nose and throat specialists have warned. Ryan W. Miller reports in USA Today that the American Academy of Otolaryngology – Head and Neck Surgery and ENT UK, citing a growing number of cases around the globe, each issued warnings about patients who tested positive for the new coronavirus with the only symptom being a lost or altered sense of smell or taste. 

  • FDA Updates COVID-19 Testing Guidelines to Allow Self-Swab Tests

    The FDA has updated its guidelines for COVID-19 testing procedures to make the process easier and less uncomfortable for patients, as well as to help limit the impact of testing on the supply of personal protective equipment (PPE) used by healthcare workers, including protective masks, face shields, gloves and gowns. Darrell Etherington reports in Techcrunch that the change means that people taking a test will be able to conduct their own swab, which will involve swabbing shallowly in their nose. 

  • Moderna Could Make Experimental COVID-19 Vaccine Available to Healthcare Workers by Fall

    There are some hard limits to the vaccine development process that mean we are not going to see any preventative immune therapies to fight the new coronavirus for at least a year to 18 months. Darrell Etherington reports in Techcrunch, however, that Moderna, which is behind the first potential vaccine to enter human clinical trials in the U.S., provided new info on Monday that indicates it will seek to provide access to the vaccine to a limited group, likely consisting of healthcare workers, by as early as this fall.